» Articles » PMID: 26666417

Lusutrombopag: First Global Approval

Overview
Journal Drugs
Specialty Pharmacology
Date 2015 Dec 16
PMID 26666417
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

Lusutrombopag (Mulpleta®) is an orally bioavailable, small molecule thrombopoietin (TPO) receptor agonist being developed by Shionogi for chronic liver disease (CLD) patients with thrombocytopenia prior to elective invasive surgery. Lusutrombopag acts selectively on the human TPO receptor and activates signal transduction pathways that promote the proliferation and differentiation of bone marrow cells into megakaryocytes, thereby increasing platelet levels. In September 2015, lusutrombopag received its first global approval in Japan for the improvement of CLD-associated thrombocytopenia in patients scheduled to undergo elective invasive procedures. This article summarizes the milestones in the development of lusutrombopag leading to this first approval.

Citing Articles

Thrombopoietin Receptor Agonists in Post-Hematopoietic Cell Transplantation Complicated by Prolonged Thrombocytopenia: A Comprehensive Review.

Elsayed A, Elsayed B, Elmarasi M, Elsabagh A, Elsayed E, Elmakaty I Immunotargets Ther. 2024; 13:461-486.

PMID: 39290805 PMC: 11407319. DOI: 10.2147/ITT.S463384.


A practical guide to the management of immune thrombocytopenia co-existing with acute coronary syndrome.

Rahhal A, Provan D, Ghanima W, Gonzalez-Lopez T, Shunnar K, Najim M Front Med (Lausanne). 2024; 11:1348941.

PMID: 38665297 PMC: 11043582. DOI: 10.3389/fmed.2024.1348941.


Knowledge map of thrombopoietin receptor agonists: A bibliometric analysis.

Hu R, Guo S, Liu M Heliyon. 2024; 10(1):e24051.

PMID: 38268581 PMC: 10806291. DOI: 10.1016/j.heliyon.2024.e24051.


Rituximab resistance in ITP and beyond.

Xiao Z, Murakhovskaya I Front Immunol. 2023; 14:1215216.

PMID: 37575230 PMC: 10422042. DOI: 10.3389/fimmu.2023.1215216.


Minimum platelet count threshold before invasive procedures in cirrhosis: Evolution of the guidelines.

Biolato M, Vitale F, Galasso T, Gasbarrini A, Grieco A World J Gastrointest Surg. 2023; 15(2):127-141.

PMID: 36896308 PMC: 9988645. DOI: 10.4240/wjgs.v15.i2.127.


References
1.
Poordad F . Review article: thrombocytopenia in chronic liver disease. Aliment Pharmacol Ther. 2007; 26 Suppl 1:5-11. DOI: 10.1111/j.1365-2036.2007.03510.x. View

2.
McCormack P . Eltrombopag: a review of its use in patients with severe aplastic anaemia. Drugs. 2015; 75(5):525-31. DOI: 10.1007/s40265-015-0363-4. View

3.
Nguyen T, Palmaro A, Montastruc F, Lapeyre-Mestre M, Moulis G . Signal for Thrombosis with Eltrombopag and Romiplostim: A Disproportionality Analysis of Spontaneous Reports Within VigiBase®. Drug Saf. 2015; 38(12):1179-86. DOI: 10.1007/s40264-015-0337-1. View

4.
Garnock-Jones K . Eltrombopag: a review of its use in treatment-refractory chronic primary immune thrombocytopenia. Drugs. 2011; 71(10):1333-53. DOI: 10.2165/11207390-000000000-00000. View

5.
Afdhal N, McHutchison J, Brown R, Jacobson I, Manns M, Poordad F . Thrombocytopenia associated with chronic liver disease. J Hepatol. 2008; 48(6):1000-7. DOI: 10.1016/j.jhep.2008.03.009. View